NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has struck an agreement with Illumina to develop in vitro diagnostic kits for sequencing tests, the company said today.

Under the agreement, HTG will have the right to develop certain IVD test kits that use Illumina's sequencing technology.

HTG, based in Tucson, Ariz., has developed the HTG Edge platform, which uses the company's proprietary nuclease protection probe chemistry to prepare samples without the need to extract DNA or RNA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.